Description
Manufacturer
Pfizer Manufacturing Deutschland GmbH.(GERMANY)
Registraction Number
MAL24066001AZ
Content:
- Active Ingredient: Abrocitinib 50 mg
- Excipients/Inactive Ingredients: Microcrystalline cellulose, Anhydrous dibasic calcium phosphate, Sodium starch glycolate, Magnesium stearate, Hypromellose (E464), Titanium dioxide (E171), Lactose monohydrate, Macrogol, Triacetin (E1518), Iron red oxide (E172).
Indications:
Cibinqo is indicated for the treatment of adults and pediatric patients aged 12 years and older with refractory, moderate-to-severe atopic dermatitis (eczema) whose disease is not adequately controlled with other systemic drug products, including biologics, or when the use of those therapies is inadvisable.
Instructions:
- Dosage:
- The recommended starting dose is 100 mg or 200 mg once daily, based on individual patient characteristics.
- Upon disease control, the dose should be decreased to 100 mg once daily.
- If disease control is not maintained after dose reduction, re-treatment with 200 mg once daily can be considered.
- Administration:
- Take Cibinqo once a day, at the same time each day.
- Swallow the tablet whole with water and do not crush, chew, or break it.
- You may take Cibinqo with or without food.
- Monitoring:
- Regular monitoring by a dermatologist or physician specializing in atopic dermatitis is recommended.
- Watch for signs of adverse effects, such as venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and malignancy.
More detail about Complete Wellness
Malaysia
